C-Vad™ Vaginal Insert

CPSI is also developing C-Vad, a controlled-release vaginal insert to treat bacterial vaginosis. Bacterial vaginosis is one of the three most common vaginal infections in women. It is usually caused by an imbalance of the normally existing microorganisms living in the vagina. It may cause vaginal discharge and an unpleasant odor. Recent studies also suggest that bacterial vaginosis may be implicated in some cases of pre-term labor.

C-Vad delivers a measured amount of the antibiotic clindamycin over a 12-hour period. Clindamycin is currently used for the treatment of bacterial vaginosis in cream, ovule and oral formulations. Each of these formulations has drawbacks: oral clindamycin often causes significant side effects, while the vaginal cream and ovule formulations may leak out, resulting in discomfort, embarrassment and underdosing. CPSI’s vaginal delivery system reduces systemic exposure and, therefore, side effects. It also delivers the drug in a precise dose, without the messiness of a cream or ovule.

CPSI is seeking licensing partners for C-Vad around the world.